Compound class:
Synthetic organic
Comment: This compound is predicted to be the active version of the TLR7 agonist prodrug polvitolimod. It is claimed as compound 27 in Primmune Therapeutics' patent WO2019226977A1 [3]. TLR7 agonists are predicted to offer clinical benefit in patients with severe COVID-19 [2], since some loss-of-function variants in TLR7 are associated with increased COVID-19 disease severity (likely via blunted type I IFN production) [1]. We can make a provisional link between compound 27 and the active TLR7 agonist PRX034.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Classification | |
Compound class | Synthetic organic |
Prodrug | polvitolimod |
IUPAC Name |
2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione |
Database Links | |
GtoPdb PubChem SID | 464244118 |
PubChem CID | 153282971 |
Search Google for chemical match using the InChIKey | TVTJUIAKQFIXCE-HUKYDQBMSA-N |
Search Google for chemicals with the same backbone | TVTJUIAKQFIXCE |
UniChem Compound Search for chemical match using the InChIKey | TVTJUIAKQFIXCE-HUKYDQBMSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | TVTJUIAKQFIXCE-HUKYDQBMSA-N |